Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Mol Cancer Ther. 2021 Nov 17;21(2):322–335. doi: 10.1158/1535-7163.MCT-21-0344

Figure 3.

Figure 3

Combination of capmatinib and merestinib achieve cellular synergy and highest combined dose response in vitro. A, MET TKI type I/type II combination effect on mixtures of TPR-MET mutant Ba/F3 cell lines was assessed using the Bliss independence dose-response surface model. B, MET TKI type I/type II combination effect on each individual TPR-MET mutant Ba/F3 cell line was assessed using the Bliss independence dose-response surface model. C, Matrices of combined dose response of TPR-MET mutant Ba/F3 cell line mixtures subjected to MET TKI type I/type II combination treatments, expressed in terms of viability.